James E. Dentzer
2006 - Amicus Therapeutics
In 2006, James E. Dentzer earned a total compensation of $490.2K as Chief Financial Officer at Amicus Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $84,000 |
|---|---|
| Option Awards | $13,822 |
| Salary | $70,000 |
| Stock Awards | $22,875 |
| Other | $299,461 |
| Total | $490,158 |
Dentzer received $299.5K in other compensation, accounting for 61% of the total pay in 2006.
Dentzer also received $84K in non-equity incentive plan, $13.8K in option awards, $70K in salary and $22.9K in stock awards.
Rankings
In 2006, James E. Dentzer's compensation ranked 4,730th out of 7,022 executives tracked by ExecPay. In other words, Dentzer earned more than 32.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,730 out of 7,022 | 33rd |
Division Manufacturing | 1,597 out of 2,413 | 34th |
Major group Chemicals And Allied Products | 418 out of 673 | 38th |
Industry group Drugs | 299 out of 518 | 42nd |
Industry Pharmaceutical Preparations | 220 out of 355 | 38th |
Source: SEC filing on April 24, 2009.
Dentzer's colleagues
We found four more compensation records of executives who worked with James E. Dentzer at Amicus Therapeutics in 2006.